DK174978B1 - Anvendelse af human koagulationsfaktor XIII til fremstilling af et lægemiddel til hindring af intraventrikulær blødning hos for tidligt fødte børn - Google Patents
Anvendelse af human koagulationsfaktor XIII til fremstilling af et lægemiddel til hindring af intraventrikulær blødning hos for tidligt fødte børn Download PDFInfo
- Publication number
- DK174978B1 DK174978B1 DK198900838A DK83889A DK174978B1 DK 174978 B1 DK174978 B1 DK 174978B1 DK 198900838 A DK198900838 A DK 198900838A DK 83889 A DK83889 A DK 83889A DK 174978 B1 DK174978 B1 DK 174978B1
- Authority
- DK
- Denmark
- Prior art keywords
- factor xiii
- coagulation factor
- drug
- precipitate
- preparation
- Prior art date
Links
- 108010071289 Factor XIII Proteins 0.000 title claims abstract description 42
- 206010022840 Intraventricular haemorrhage Diseases 0.000 title claims abstract description 19
- 239000003814 drug Substances 0.000 title claims description 6
- 229940079593 drug Drugs 0.000 title claims description 5
- 229940105784 coagulation factor xiii Drugs 0.000 title claims description 4
- 230000002028 premature Effects 0.000 title abstract description 4
- 238000002360 preparation method Methods 0.000 title description 10
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000002347 injection Methods 0.000 abstract description 7
- 239000007924 injection Substances 0.000 abstract description 7
- 230000002265 prevention Effects 0.000 abstract description 3
- 229940012444 factor xiii Drugs 0.000 description 34
- 239000000243 solution Substances 0.000 description 17
- 239000002244 precipitate Substances 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 208000032843 Hemorrhage Diseases 0.000 description 9
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 208000034158 bleeding Diseases 0.000 description 6
- 230000000740 bleeding effect Effects 0.000 description 6
- 229940090044 injection Drugs 0.000 description 6
- 210000002381 plasma Anatomy 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 210000002826 placenta Anatomy 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 230000002861 ventricular Effects 0.000 description 4
- 108010073385 Fibrin Proteins 0.000 description 3
- 102000009123 Fibrin Human genes 0.000 description 3
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 3
- 102000005686 Serum Globulins Human genes 0.000 description 3
- 108010045362 Serum Globulins Proteins 0.000 description 3
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 3
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 3
- 235000011130 ammonium sulphate Nutrition 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229950003499 fibrin Drugs 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- IYLLULUTZPKQBW-UHFFFAOYSA-N Acrinol Chemical compound CC(O)C(O)=O.C1=C(N)C=CC2=C(N)C3=CC(OCC)=CC=C3N=C21 IYLLULUTZPKQBW-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 229960002449 glycine Drugs 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- HBGOLJKPSFNJSD-UHFFFAOYSA-N Etamsylate Chemical compound CC[NH2+]CC.OC1=CC=C(O)C(S([O-])(=O)=O)=C1 HBGOLJKPSFNJSD-UHFFFAOYSA-N 0.000 description 1
- 108010000196 Factor XIIIa Proteins 0.000 description 1
- 108010058861 Fibrin Fibrinogen Degradation Products Proteins 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 210000003017 ductus arteriosus Anatomy 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229940011899 ethamsylate Drugs 0.000 description 1
- 229940049010 factor xiii injection Drugs 0.000 description 1
- 239000000208 fibrin degradation product Substances 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000004023 fresh frozen plasma Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013905 glycine and its sodium salt Nutrition 0.000 description 1
- -1 glycine) Chemical class 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000003434 inspiratory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Heart & Thoracic Surgery (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3964688 | 1988-02-24 | ||
| JP63039646A JPH01216939A (ja) | 1988-02-24 | 1988-02-24 | 末熟児頭蓋内出血阻止剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DK83889D0 DK83889D0 (da) | 1989-02-23 |
| DK83889A DK83889A (da) | 1989-08-25 |
| DK174978B1 true DK174978B1 (da) | 2004-04-05 |
Family
ID=12558846
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK198900838A DK174978B1 (da) | 1988-02-24 | 1989-02-23 | Anvendelse af human koagulationsfaktor XIII til fremstilling af et lægemiddel til hindring af intraventrikulær blødning hos for tidligt fødte børn |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US5114916A (enExample) |
| EP (1) | EP0330049B1 (enExample) |
| JP (1) | JPH01216939A (enExample) |
| KR (1) | KR0137476B1 (enExample) |
| AT (1) | ATE94070T1 (enExample) |
| AU (1) | AU613154B2 (enExample) |
| CA (1) | CA1332352C (enExample) |
| DE (1) | DE68908913T2 (enExample) |
| DK (1) | DK174978B1 (enExample) |
| ES (1) | ES2059588T3 (enExample) |
| IE (1) | IE63656B1 (enExample) |
| PT (1) | PT89802B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5612456A (en) * | 1988-11-14 | 1997-03-18 | Zymogenetics, Inc. | Factor XIII compositions |
| EP0624095B2 (en) * | 1991-12-31 | 2005-07-20 | Zymogenetics, Inc. | Methods and compositions for reducing blood loss |
| WO1993020837A1 (fr) * | 1992-04-21 | 1993-10-28 | Ajinomoto Co., Inc. | Remede contre les plaies |
| DE69326349T2 (de) * | 1992-11-12 | 2000-03-02 | Mayberg, Marc R. | Verwendung von lokal appliziertem faktor xiii zur verhinderung von blutungen |
| JPH07328108A (ja) * | 1994-06-10 | 1995-12-19 | Ajinomoto Co Inc | 生体組織接着剤及び血液凝固剤 |
| ATE298251T1 (de) | 1998-08-06 | 2005-07-15 | Mountain View Pharmaceuticals | Peg-uricase konjugate und verwendung davon |
| JP2008510476A (ja) * | 2004-08-27 | 2008-04-10 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 生物学的材料からのｘｉｉｉ因子ポリペプチドの精製 |
| US8461302B2 (en) * | 2004-11-23 | 2013-06-11 | Zymogenetics, Inc. | Purification of recombinant human factor XIII |
| TWI418564B (zh) * | 2005-04-11 | 2013-12-11 | 沙凡特藥品公司 | 利用陽離子界面活性劑之蛋白質純化 |
| KR20080009111A (ko) | 2005-04-11 | 2008-01-24 | 새비언트 파마수티컬즈 인크. | 유레이트 옥시다아제의 변이형 및 이의 용도 |
| KR101288027B1 (ko) * | 2006-04-12 | 2013-07-22 | 새비언트 파마수티컬즈 인크. | 양이온 계면활성제를 이용한 단백질 정제 방법 |
| JP2012531596A (ja) | 2009-06-25 | 2012-12-10 | サヴィエント・ファーマシューティカルズ・インコーポレイテッド | Ｐｅｇ化ウリカーゼ療法における血清尿酸をモニタリングすることにより注入反応の危険性および抗体媒介性効果消失を予測するための方法およびキット |
| CN116637177A (zh) | 2016-11-11 | 2023-08-25 | 好利恩治疗美国公司 | 泼尼松和尿酸酶分子的组合疗法及其用途 |
| WO2020160325A1 (en) | 2019-01-30 | 2020-08-06 | Horizon Pharma Rheumatology Llc | Reducing immunogenicity to pegloticase |
| US12121566B2 (en) | 2019-01-30 | 2024-10-22 | Horizon Therapeutics Usa, Inc. | Methods for treating gout |
| US12269875B2 (en) | 2023-08-03 | 2025-04-08 | Jeff R. Peterson | Gout flare prevention methods using IL-1BETA blockers |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3717708A (en) * | 1968-10-24 | 1973-02-20 | Cutter Lab | Blood coagulation complex |
| DE2063070C3 (de) * | 1970-12-22 | 1975-07-24 | Behringwerke Ag, 3550 Marburg | Verfahren zur Herstellung eines Arzneimittels mit fibrinstabilisierender Wirkung |
| DE3622642A1 (de) * | 1986-07-05 | 1988-01-14 | Behringwerke Ag | Einkomponenten-gewebekleber sowie verfahren zu seiner herstellung |
| DK175919B1 (da) * | 1986-09-19 | 2005-06-27 | Univ Washington | Ekspression af biologisk aktiv faktor XIII |
-
1988
- 1988-02-24 JP JP63039646A patent/JPH01216939A/ja active Granted
-
1989
- 1989-02-14 ES ES89102471T patent/ES2059588T3/es not_active Expired - Lifetime
- 1989-02-14 DE DE89102471T patent/DE68908913T2/de not_active Expired - Lifetime
- 1989-02-14 EP EP89102471A patent/EP0330049B1/en not_active Expired - Lifetime
- 1989-02-14 AT AT89102471T patent/ATE94070T1/de not_active IP Right Cessation
- 1989-02-23 KR KR1019890002127A patent/KR0137476B1/ko not_active Expired - Lifetime
- 1989-02-23 CA CA000591929A patent/CA1332352C/en not_active Expired - Lifetime
- 1989-02-23 IE IE58089A patent/IE63656B1/en not_active IP Right Cessation
- 1989-02-23 PT PT89802A patent/PT89802B/pt not_active IP Right Cessation
- 1989-02-23 AU AU30243/89A patent/AU613154B2/en not_active Expired
- 1989-02-23 DK DK198900838A patent/DK174978B1/da not_active IP Right Cessation
-
1990
- 1990-02-14 US US07/480,358 patent/US5114916A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0378850B2 (enExample) | 1991-12-17 |
| PT89802B (pt) | 1994-04-29 |
| EP0330049B1 (en) | 1993-09-08 |
| DE68908913T2 (de) | 1994-01-27 |
| KR890012659A (ko) | 1989-09-18 |
| ATE94070T1 (de) | 1993-09-15 |
| IE63656B1 (en) | 1995-05-31 |
| DE68908913D1 (de) | 1993-10-14 |
| US5114916A (en) | 1992-05-19 |
| PT89802A (pt) | 1989-10-04 |
| EP0330049A2 (en) | 1989-08-30 |
| JPH01216939A (ja) | 1989-08-30 |
| EP0330049A3 (en) | 1991-01-30 |
| AU613154B2 (en) | 1991-07-25 |
| CA1332352C (en) | 1994-10-11 |
| AU3024389A (en) | 1989-08-24 |
| ES2059588T3 (es) | 1994-11-16 |
| IE890580L (en) | 1989-08-24 |
| DK83889A (da) | 1989-08-25 |
| DK83889D0 (da) | 1989-02-23 |
| KR0137476B1 (ko) | 1998-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6825323B2 (en) | Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen and methods of using same | |
| Getahun et al. | Epidemic of neurolathyrism in Ethiopia | |
| US5114916A (en) | Therapeutic agent for the prevention of intraventricular hemorrhage in premature infants | |
| US4451454A (en) | Prophylaxis and treatment of thromboembolic disorders in man and in warm-blooded animals with bicarbonate salts of alkali metals | |
| US9233126B2 (en) | Platelet-rich plasma compositions | |
| JPS597693B2 (ja) | 抗トロンビン製剤及びその製法 | |
| RU2252783C2 (ru) | Фармацевтический препарат, содержащий низкомолекулярный ингибитор тромбина и его пролекарство | |
| TW201425332A (zh) | 抗凝血酶用於體外膜氧合之用途 | |
| JPH0425255B2 (enExample) | ||
| CA2091134C (en) | Therapeutic agent for threatened abortion | |
| Tso et al. | Venous thrombosis in haemoglobin H disease after splenectomy | |
| EP0278416A2 (en) | Use of human blood coagulation factor XIII for the treatment of ulcerative colitis | |
| JPH03135918A (ja) | 免疫賦活剤 | |
| RU2119316C1 (ru) | Способ лечения кровоизлияний во внутренние среды и оболочки глаза | |
| AU2001227771B2 (en) | Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen | |
| US5164373A (en) | Therapeutic agent for diabetic gangrene comprising factor XIII | |
| AU2001227771A1 (en) | Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen | |
| Fuerth et al. | Surgery in a hemophiliac child with intracranial hemorrhage | |
| US7074774B2 (en) | Use of N-acetyl-D-glucosamine in the manufacture of pharmaceutical useful for treating cardio-cerebrovascular anoxemia | |
| Ghareeb et al. | Anti-hemorrhagic agents | |
| JP2526073B2 (ja) | 異常破水治療剤 | |
| JOHNSON et al. | of a Factor VIII Concentrateđ | |
| WO2025254209A1 (ja) | クエン酸を含む血液由来成長因子含有組成物及びその調製方法 | |
| JakloyazAy | CONGENITAL AFIBRINOGENAEMIA: DIAGNOSIS, CLINICAL FEATURES, FOLLOW-UP STUDY | |
| CN118903379A (zh) | ShSPI在制备治疗或预防血栓类疾病药物中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUP | Patent expired |